Heron Therapeutics (NASDAQ:HRTX – Get Free Report) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, November 12th. Analysts expect Heron Therapeutics to post earnings of ($0.03) per share for the quarter. Parties interested in registering for the company’s conference call can do so using this link.
Heron Therapeutics (NASDAQ:HRTX – Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The firm had revenue of $36.02 million for the quarter, compared to analysts’ expectations of $35.35 million. During the same period in the prior year, the company earned ($0.35) EPS.
Heron Therapeutics Stock Down 3.9 %
NASDAQ:HRTX traded down $0.07 during trading hours on Tuesday, hitting $1.71. 346,938 shares of the company traded hands, compared to its average volume of 2,396,292. Heron Therapeutics has a one year low of $0.50 and a one year high of $3.93. The company has a market cap of $259.36 million, a PE ratio of -5.42 and a beta of 1.81. The firm’s 50-day simple moving average is $1.88 and its 200-day simple moving average is $2.58.
Analysts Set New Price Targets
View Our Latest Analysis on HRTX
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
See Also
- Five stocks we like better than Heron Therapeutics
- The How And Why of Investing in Oil Stocks
- Insider Buying Signals Upside for These 3 Stocks
- How to Evaluate a Stock Before Buying
- These 2 Big Players Are Set to Compete With Elon Musk’s Starlink
- The 3 Best Retail Stocks to Shop for in August
- NXP Semiconductors Nears Rock Bottom: A Buy Signal Is Expected
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.